Trends in Neonatal Opioid Withdrawal Syndrome and Opioid Exposure Diagnoses Among Infants With Private Health Insurance, 2016-2021: Introduction of the P04.14 ICD-10-CM Code

• Published in: Public health reports (1974) 2024-01, Vol.139 (1), p.88-93
• Main Authors: Campbell, Angela G., Zhang, Pengyue, Rosenman, Marc B., Scott, Emily, Wiehe, Sarah E.
• Format: Article
• Language: English
• Subjects: Analgesics, Opioid - adverse effects; Classification; Clinical significance; Codes; Drug abuse; Drug addiction; Drug withdrawal; Drugs; Exposure; Health care industry; Health insurance; Humans; Infant, Newborn; Infants; Insurance; Insurance, Health; International Classification of Diseases; Maternal and infant welfare; Medical diagnosis; Narcotics; Neonatal abstinence syndrome; Neonatal Abstinence Syndrome - epidemiology; Neonates; Newborn babies; Opioid-Related Disorders - epidemiology; Opioids; Rates; Reduction; Signs and symptoms; Substance Withdrawal Syndrome; Symptoms; United States - epidemiology; Withdrawal
• ISSN: 0033-3549; 1468-2877
• DOI: 10.1177/00333549231162375

Objective: The opioid epidemic has led to a surge in diagnoses of neonatal opioid withdrawal syndrome (NOWS). Many states track the incidence of NOWS by using the P96.1 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code for “neonatal withdrawal symptoms from maternal use of drugs of addiction.” In October 2018, an ICD-10-CM code for neonatal opioid exposure (P04.14) was introduced. This code can be used when an infant is exposed to opioids in utero but does not have clinically significant withdrawal symptoms. We analyzed the effect of the P04.14 code on the incidence rate of NOWS (P96.1) and “other” neonatal drug exposure diagnoses (P04.49). Methods: We used private health insurance data collected for infants in the United States from the first quarter of 2016 through the third quarter of 2021 to describe incidence rates for each code over time and examine absolute and percentage changes before and after the introduction of code P04.14. Results: The exclusive use of code P96.1 declined from an incidence rate per 1000 births of 1.08 in 2016-2018 to 0.70 in 2019-2021, a −35.7% (95% CI, −47.6% to −23.8%) reduction. Use of code P04.49 only declined from an incidence rate of 2.34 in 2016-2018 to 1.64 in 2019-2021, a −30.0% (95% CI, −36.4% to −23.7%) reduction. Use of multiple codes during the course of treatment increased from an average incidence per 1000 births of 0.56 in 2016-2018 to 0.79 in 2019-2021, a 45.5% (95% CI, 24.8%-66.1%) increase. Conclusion: The introduction of ICD-10-CM code P04.14 altered the use of other neonatal opioid exposure codes. The use of multiple codes increased, indicating that some ambiguity may exist about which ICD-10-CM code is most appropriate for a given set of symptoms.